Article
Hikma v. Amarin: What The Supreme Court’s Decision Means For Skinny Labels And Induced Infringement
The Supreme Court's unanimous decision in Hikma v. Amarin resets the standard for pleading induced patent infringement, requiring focus on the accused party's affirmative actions rather than potential downstream infringer responses. This ruling has significant implications for brand manufacturers pursuing follow-on drug indications and generic manufacturers seeking skinny label approvals for unpatented indications.
Wolf, Greenfield & Sacks, P.C.
